These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23942542)

  • 41. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring.
    Pea F; Milaneschi R; Baraldo M; Lugatti E; Talmassons G; Furlanut M
    Ther Drug Monit; 2000 Aug; 22(4):386-91. PubMed ID: 10942176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration.
    Cekiç O; Batman C; Yasar U; Başci NE; Bozkurt A; Kayaalp SO
    Eye (Lond); 1999 Aug; 13 ( Pt 4)():555-8. PubMed ID: 10692930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.
    Szałek E; Kamińska A; Gozdzik-Spychalska J; Grześkowiak E; Batura-Gabryel H
    Acta Pol Pharm; 2011; 68(5):777-83. PubMed ID: 21928725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients.
    Guay DR; Awni WM; Peterson PK; Obaid S; Stein D; Breitenbucher R; Matzke GR
    Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):279-84. PubMed ID: 3410603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
    Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
    Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.
    Phillips JO; Olsen KM; Rebuck JA; Rangnekar NJ; Miedema BW; Metzler MH
    Am J Gastroenterol; 2001 Feb; 96(2):367-72. PubMed ID: 11232677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.
    Yuk JH; Nightingale CH; Sweeney KR; Quintiliani R; Lettieri JT; Frost RW
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1118-20. PubMed ID: 2506806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC.
    Khan MK; Khan MF
    Pak J Pharm Sci; 2008 Jul; 21(3):299-306. PubMed ID: 18614429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay.
    Issa MM; Nejem RM; El-Abadla NS; El-Naby MK; Roshdy AA; Kheiralla ZA
    Clin Drug Investig; 2007; 27(7):463-7. PubMed ID: 17563126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections.
    Cios A; Wyska E; Szymura-Oleksiak J; Grodzicki T
    Exp Gerontol; 2014 Sep; 57():107-13. PubMed ID: 24862289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose.
    Lugg J; Lettieri J; Stass H; Agarwal V
    J Chemother; 2008 Apr; 20(2):213-8. PubMed ID: 18467248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of enrofloxacin in turkeys.
    Dimitrova DJ; Lashev LD; Yanev SG; Pandova B
    Res Vet Sci; 2007 Jun; 82(3):392-7. PubMed ID: 17107697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding.
    Hsieh WJ; Lin HC; Hwang SJ; Hou MC; Lee FY; Chang FY; Lee SD
    Am J Gastroenterol; 1998 Jun; 93(6):962-6. PubMed ID: 9647029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
    Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC
    Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory Effects of Multiple-Dose Treatment with Baicalein on the Pharmacokinetics of Ciprofloxacin in Rats.
    Hwang YH; Yang HJ; Kim DG; Ma JY
    Phytother Res; 2017 Jan; 31(1):69-74. PubMed ID: 27671796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.